News

Video

Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)

Author(s):

Enrique Grande, MD, PhD, Msc

Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma.

Related Videos
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
A Phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent high-grade glioma (HGG) patients with EGFR alterations or fusions
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Related Content